Angstrom Bio employs novel nucleotide chemistry and machine learning to analyze genetic sequences, providing precise insights into their functions. This technology addresses the inefficiencies in genomic data analysis, enabling faster and more accurate results for research and therapeutic applications.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of genomic data analysis often suffer from inefficiencies, leading to slower and less accurate results in research and therapeutic applications. Analyzing genetic sequences to understand their functions can be a bottleneck in developing new diagnostics and treatments.
Solution
Angstrom Bio leverages advanced nucleotide chemistry and machine learning to provide precise insights into genetic sequence functions. Their Angstrom Massively Parallel Diagnostic (AMPD) platform enables population-scale molecular diagnostics with high throughput and sensitivity at a scale-enabling cost. The platform is designed for cost-effective, massively-parallel, NGS-based viral diagnostics, including COVID-19. Angstrom Bio also offers computational optimization of both _in vitro_ and immunization-derived antibodies to optimize research and therapeutics.
Target Audience
The primary audience includes researchers, healthcare providers, and diagnostic labs seeking efficient and accurate genomic analysis for diagnostic and therapeutic applications.
Features
- Massively parallel diagnostic platform for population-scale molecular analysis
- Utilizes amplicon sequencing and machine learning for enhanced accuracy
- High-throughput processing for rapid results
- Unrivaled sensitivity in detecting genetic sequences
- Cost-effective solution for large-scale diagnostics
- Computational optimization of antibodies for research and therapeutic development